4DMedical Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Andreas Fouras

Chief Executive Officer (CEO)

AU$988.1k

Compensación total

Porcentaje del salario del CEO	56.4%
Permanencia del CEO	no data
Participación del CEO	0.2%
Permanencia media de la dirección	1.8yrs
Promedio de permanencia en la Junta Directiva	5.3yrs

Actualizaciones recientes de la dirección

4DMedical Limited's (ASX:4DX) CEO Compensation Is Looking A Bit Stretched At The Moment

Oct 26

Recent updates

4DMedical Limited's (ASX:4DX) CEO Compensation Is Looking A Bit Stretched At The Moment

Oct 26

Here's Why We're Not At All Concerned With 4DMedical's (ASX:4DX) Cash Burn Situation

Jun 16

Here's Why We're Not Too Worried About 4DMedical's (ASX:4DX) Cash Burn Situation

Jun 05

Is 4DMedical Limited's (ASX:4DX) Shareholder Ownership Skewed Towards Insiders?

Feb 20

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Andreas Fouras en comparación con los beneficios de 4DMedical?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-AU$31m
Sep 30 2023	n/a	n/a	-AU$31m
Jun 30 2023	AU$988k	AU$557k	-AU$31m
Mar 31 2023	n/a	n/a	-AU$30m
Dec 31 2022	n/a	n/a	-AU$28m
Sep 30 2022	n/a	n/a	-AU$26m
Jun 30 2022	AU$821k	AU$519k	-AU$25m
Mar 31 2022	n/a	n/a	-AU$23m
Dec 31 2021	n/a	n/a	-AU$21m
Sep 30 2021	n/a	n/a	-AU$21m
Jun 30 2021	AU$646k	AU$502k	-AU$21m
Mar 31 2021	n/a	n/a	-AU$26m
Dec 31 2020	n/a	n/a	-AU$30m
Sep 30 2020	n/a	n/a	-AU$26m
Jun 30 2020	AU$1m	AU$435k	-AU$22m
Mar 31 2020	n/a	n/a	-AU$16m
Dec 31 2019	n/a	n/a	-AU$9m
Sep 30 2019	n/a	n/a	-AU$8m
Jun 30 2019	AU$366k	AU$360k	-AU$6m

Compensación vs. Mercado: La compensación total ($USD642.92K) de Andreas está en línea con el promedio de empresas de tamaño similar en el mercado Australian ($USD638.13K).

Compensación vs. Ingresos: La compensación de Andreas ha aumentado mientras la empresa no es rentable.

CEO

Andreas Fouras

no data

Permanencia

AU$988,105

Compensación

Dr. Andreas Fouras, BEng, MEngSc(Res), Ph.D. M.A.I.C.D. is Founder of 4DMedical Limited and serves as its Managing Director, Chief Executive Officer & Director and served as its Chief Technology Officer. D...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Andreas Fouras	Founder	no data	AU$988.11k	0.22% A$ 531.0k
Simon Glover	Chief Financial Officer	1.8yrs	AU$360.91k	sin datos
John Livingston	Executive Director	1.9yrs	AU$297.18k	0.49% A$ 1.2m
Naomi Lawrie	Company Secretary & General Counsel	less than a year	sin datos	sin datos
Rachael Tenkaten	Chief of Staff	1.8yrs	sin datos	sin datos
Aidan Jamison	Senior Vice President of Engineering	no data	sin datos	sin datos
Michael Curtis	Chief Software Architect	no data	sin datos	sin datos
Jon Dusting	Chief Research Officer	1.8yrs	sin datos	sin datos
Jason Kirkness	Senior Vice President of Medical & Clinical Affairs	1.8yrs	sin datos	sin datos
Matt Tucker	Chief Commercial Officer	1.3yrs	sin datos	sin datos
Greg Mogel	Senior VP & Executive Medical Director	no data	sin datos	sin datos

1.8yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 4DX no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Andreas Fouras	Founder	no data	AU$988.11k	0.22% A$ 531.0k
John Livingston	Executive Director	6.1yrs	AU$297.18k	0.49% A$ 1.2m
Sam Hupert	Member of Advisory Board	5.3yrs	sin datos	sin datos
Robert Figlin	Independent Non-Executive Director	7.3yrs	AU$63.20k	0.13% A$ 319.8k
Julian Sutton	Non-Executive Director	6.6yrs	AU$217.60k	0.12% A$ 295.7k
Raymond Casciari	Clinical Chair of the Advisory Board	4.9yrs	sin datos	sin datos
Lilian Bianchi	Independent Non-Executive Chair	4.3yrs	AU$78.20k	0.024% A$ 57.4k
Bruce Thompson	Member of Advisory Board	no data	sin datos	sin datos
Geraldine McGinty	Independent Non-Executive Director	less than a year	sin datos	0.010% A$ 24.6k

5.3yrs

Permanencia media

Junta con experiencia: La junta directiva de 4DX se considera experimentada (5.3 años de antigüedad promedio).

4DMedical Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

4DMedical Limited Announces Resignation of Evonne Collier as a Non-Executive Director, Chair of the Remuneration and Nomination Committee

4DMedical Limited's (ASX:4DX) CEO Compensation Is Looking A Bit Stretched At The Moment

4DMedical Limited Announces the Appointment of Geraldine Mcginty to the Board of Directors

4DMedical Limited, Annual General Meeting, Nov 02, 2023

4DMedical Limited Appoints Matt Tucker as Senior Vice President of Business Development and Strategy

4DMedical Limited, Annual General Meeting, Nov 03, 2022

Recent updates

Consensus revenue estimates fall by 20%

New minor risk - Profitability

No longer forecast to breakeven

Consensus revenue estimates decrease by 22%, EPS upgraded

4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 35 million.

4DMedical Limited has filed a Follow-on Equity Offering in the amount of AUD 35 million.

No longer forecast to breakeven

Price target increased by 21% to AU$1.18

4DMedical Receives U.S. FDA Clearance for CT LVAS Lung Function Scanning Software

Forecast to breakeven in 2026

New major risk - Share price stability

4DMedical Limited Announces Resignation of Evonne Collier as a Non-Executive Director, Chair of the Remuneration and Nomination Committee

4DMedical Limited's (ASX:4DX) CEO Compensation Is Looking A Bit Stretched At The Moment

New minor risk - Market cap size

4DMedical Limited Announces the Appointment of Geraldine Mcginty to the Board of Directors

New minor risk - Profitability

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2026

New major risk - Revenue and earnings growth

4DMedical Limited, Annual General Meeting, Nov 02, 2023

Forecast to breakeven in 2026

Here's Why We're Not At All Concerned With 4DMedical's (ASX:4DX) Cash Burn Situation

First half 2023 earnings released: AU$0.06 loss per share (vs AU$0.04 loss in 1H 2022)

Consensus revenue estimates increase by 55%

We Think 4DMedical (ASX:4DX) Needs To Drive Business Growth Carefully

4DMedical Limited Appoints Matt Tucker as Senior Vice President of Business Development and Strategy

4Dmedical Unveils XV Scanner

Price target increased to AU$1.33

4DMedical Limited Releases CT LVAS in Australia

American Medical Association Current Procedural Terminology Editorial Panel Accepts 4Dmedical's Application for the Addition of A New Category III CPT Code

Is 4DMedical (ASX:4DX) In A Good Position To Deliver On Growth Plans?

4DMedical Limited, Annual General Meeting, Nov 03, 2022

4DMedical Limited Updates Vanderblit 'Burn Pit' Trial Hits Primary Endpoint

Consensus forecasts updated

Full year 2022 earnings: Revenues miss analyst expectations

We're Hopeful That 4DMedical (ASX:4DX) Will Use Its Cash Wisely

4Dmedical Limited Announces CFO Changes

High number of new directors

4DMedical Limited Appoints John Livingston as Role of Senior Strategist and Executive Director

4DMedical Limited Announces Clinical Trial Results Presented At Top US Lung Conference

High number of new directors

Price target decreased to AU$1.50

Price target decreased to AU$1.50

4DMedical Limited Announces Executive Changes

We Think 4DMedical (ASX:4DX) Can Afford To Drive Business Growth

High number of new directors

4DMedical Limited Announces First Commercial Scans with I-MED to Commence in December

Full year 2021 earnings released: AU$0.082 loss per share (vs AU$0.15 loss in FY 2020)

Full year 2021 earnings released

4D Medical Announces Undertaking Clinical Trial At the John Hopkins School of Medicine in Baltimore, USA

4DMedical Limited Commences XV LVAS Clinical Trial at Johns Hopkins School of Medicine, US

Here's Why We're Not Too Worried About 4DMedical's (ASX:4DX) Cash Burn Situation

4DMedical Limited Commences Patient Recruitment for VQ Trial

New 90-day low: AU$1.65

First half 2021 earnings released: AU$0.05 loss per share (vs AU$0.04 loss in 1H 2020)

Is 4DMedical Limited's (ASX:4DX) Shareholder Ownership Skewed Towards Insiders?

4DMedical Limited Appoints Mr. Craige Pendleton-Browne as Chief Information Officer

New 90-day low: AU$2.07

4DMedical Limited Provides Update on Its First Clinical Pilot for XV Lung Ventilation Analysis Software

4DMedical Limited Completes First Commercial Scan in Australia

4Dmedical Limited Partners with University of Miami Health System to Establish the Functional Lung Imaging Research Program

4Dmedical Limited Receives TGA Approval for XV Lung Ventilation Analysis Software (XV LVAS)

Full year earnings released - AU$0.15 loss per share

Full year earnings released

4DMedical Limited Auditor Raises 'Going Concern' Doubt

4DMedical Limited Auditor Raises 'Going Concern' Doubt

First half earnings released

4DMedical Limited has completed an IPO in the amount of AUD 55.793682 million.

Análisis de compensación del CEO